Is Kwality Pharma overvalued or undervalued?

Nov 15 2025 08:10 AM IST
share
Share Via
As of November 14, 2025, Kwality Pharma is considered an attractive investment due to its undervalued status, with a PE ratio of 20.24, favorable comparisons to peers like Sun Pharma and Cipla, and a strong 172.96% return over three years, outperforming the Sensex.
As of 14 November 2025, the valuation grade for Kwality Pharma has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently deemed undervalued, supported by a PE ratio of 20.24, an EV to EBITDA ratio of 11.51, and a PEG ratio of 0.45, which suggests strong growth potential relative to its price.

In comparison to its peers, Kwality Pharma's valuation stands out favorably; for instance, Sun Pharma has a significantly higher PE ratio of 36.49, while Cipla, another attractive peer, has a PE of 22.72. This positions Kwality Pharma as a more appealing investment option within the pharmaceuticals sector. Additionally, the company's stock has outperformed the Sensex over various time frames, including a 172.96% return over three years, reinforcing its attractiveness in the market.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News